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Predicting protein–ligand binding aﬃnity and
correcting crystal structures with quantum
mechanical calculations: lactate dehydrogenase A†
Iva Lukac, a Hend Abdelhakim, a Richard A. Ward, b Stephen A. St-Gallay, c
Judith C. Madden a and Andrew G. Leach *a
Accurately computing the geometry and energy of host–guest and protein–ligand interactions requires
a physically accurate description of the forces in action. Quantum mechanics can provide this accuracy
but the calculations can require a prohibitive quantity of computational resources. The size of the
calculations can be reduced by including only the atoms of the receptor that are in close proximity to
the ligand. We show that when combined with log P values for the ligand (which can be computed
easily) this approach can signiﬁcantly improve the agreement between computed and measured binding
energies. When the approach is applied to lactate dehydrogenase A, it can make quantitative predictions
about conformational, tautomeric and protonation state preferences as well as stereoselectivity and even
identiﬁes potential errors in structures deposited in the Protein Data Bank for this enzyme. By
broadening the evidence base for these structures from only the diﬀraction data, more chemically
realistic structures can be proposed.
1 Background
The interaction of small guest molecules with larger hosts in
aqueous systems is a key component of many applications
including: sensors for in vivo use,1 enzyme catalysis,2 antibody
recognition,3 sequestration,4 purication of waste streams,5
environmental remediation,6 drug design,7 toxicology,8 and
supramolecular chemistry.9 The structures of such complexes
are routinely studied with X-ray diﬀraction experiments and
those involving proteins are deposited in the Protein Data Bank
(PDB).10 These have been investigated to learn about how
proteins and ligands interact.11 Such studies presume that the
structures are correct and of high quality based on descriptive
statistics describing how well the structure can explain the
observed diﬀraction data. Ourselves and others have found that
these statistics are not suﬃcient – chemically infeasible ligand
structures can achieve apparently better statistics.12 Quantum
mechanical (QM) calculations can provide a complementary
guide to the chemical reasonableness of structures. A recent
study illustrates the challenge: Kumar et al. contrasted
quantum mechanical calculations with deposited structures
and found a divergence between complexes of arginine (which
behaved as predicted) and lysine (which did not); the con-
trasting likelihoods of these two residue types being clearly
identiable in the electron density was not considered but
could provide an alternative interpretation of their ndings.13
Routinely allowing quantum calculations to decide when to go
beyond reliance on the diﬀraction data alone would increase
the likelihood of identifying the correct structure but requires
a method that can predict binding strength to a useful level of
accuracy. Here we propose such a method and show how it has
guided us to improved structural interpretations for an
enzyme of pharmaceutical interest. This has permitted us to
begin the process of deducing when diﬀerences in diagnostic
statistics, such as Rwork and Rfree are not signicant. Others
have previously lamented the reliance on these statistics and
particularly when they distract from achieving a sound
chemical interpretation that correctly accounts for the phys-
ical interactions at play.14
Correctly quantifying the interaction strength between a host
and a guest or a protein and a ligand computationally requires
a physically accurate description of the molecules, of the kind
provided by QM calculations. Despite signicant progress, such
calculations remain challenging because of their computational
cost. Including only the portion of the host or protein directly
involved in binding reduces this cost and examples of this
approach are mentioned in recent reviews.15,16 Related calcula-
tions see the protein or ligands split into fragments that can
then be treated with QM.17–22 Geometries generated by
a molecular dynamics simulation can be treated with QM to
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compute aﬃnities.23 Alternatively, much faster QM methods
(which are usually less general or accurate) can be applied to
larger portions of the system, or empirical corrections applied
to improve accuracy with minimal increased computing
cost.24–26
Alternative approaches to understanding the behavior of
proteins and quantifying their interaction strength with ligands
have been pursued vigorously over the past decade. The
majority of this eﬀort has been in the area of simulation and
recent advances in free energy perturbation (FEP) are particu-
larly noteworthy.27,28One signicant issue with these methods is
that (unlike quantum approaches) the parameterization
schemes that underpin the description of the ligands oen
require individual tailoring to the molecules being studied.27
Like quantum calculations, simulations require a signicant
amount of computational time to compute binding energies.
Structural biology studies oen entail generating crystalline
solids containing protein–ligand complexes. These are irradi-
ated to create X-ray diﬀraction patterns, arising from interac-
tions with electrons in the molecules. Soware is employed to
link from atomic coordinates to electron density and hence X-
ray diﬀraction patterns; thus a likely set of atomic positions
can be identied. These interpretations can be problematic and
are rarely unambiguous.12 QM calculations can support these
interpretations but it is usual for improved agreement between
predicted and observed diﬀraction patterns to determine the
structure deemed to be correct.29–34 One way to meld the
chemical insight provided by quantum chemical calculations
with the experimental data available from a diﬀraction experi-
ment is to iteratively include quantum calculations in the
renement procedure; higher quality structures of proteins and
ligands have been achieved in this way using the quantum
renement approaches pioneered by the Ryde group.30 This has
proved particularly eﬀective for metalloproteins and for
assigning protonation states.15,30,35–37 Indeed, QM-derived ideas
have been inuencing structural renement for nearly
a century. Sometimes, the diﬀraction data cannot determine the
correct structure and this is particularly the case for novel
ligands whose behavior is much less well understood than that
of proteins.38 One way alternative interpretations of the
diﬀraction data can be assessed is by examining ligand omit
maps that are created by using the coordinates of the protein to
generate phases and to use these to determine the ligand elec-
tron density that is unaccounted for.39–41
We propose an approach in which a correlation with
computed log P values provides a usefully accurate treatment that
accounts for the diﬀerences between binding energies computed
with quantum mechanics and experimentally observed values.
We style the resulting type of calculation as a “theoceptor”
(theoretical receptor) by analogy to the theozymes (theoretical
enzymes) of Houk and co-workers.42,43We show that the approach
can be applied to predicting aqueous host–guest interaction
energies in the realm of biological or supramolecular chemistry.
We also present a theoceptor for the enzyme Lactate Dehydro-
genase A (LDHA) and demonstrate the value that theoceptor
calculations can provide in terms of detailed structural insights
and improved crystallographic structures.
The current study is presented in three parts. In the rst, we
describe our approach. Subsequently, we describe our theo-
ceptor for LDHA. Finally, we show how these calculations can
increase the value of protein–ligand crystal structures and
provide alternative interpretations of the electron density for
several examples taken from LDHA.
2 Results and discussion
Quantum mechanical calculations generally deal with the gas
phase electronic energy of the system whereas experimental
observations in biological systems are related to free energies in
solution (eqn (1)).
DGbind(aq) ¼ DE + DHcorr(gas)  TDS(gas) + DDGsolv (1)
The free energy of binding in solution (DGbind(aq)) is related
to the change in gas phase electronic energy (DE, eqn (2))
computed with QM. Corrections (DHcorr) are added to obtain
gas phase enthalpies and a gas phase entropy change (DS(gas))
is computed. The change in solvation free energies (DDGsolv)
completes the link to the experimental environment.
DE ¼ Ecomplex  Eligand  Ereceptor (2)
The electronic energies in eqn (2) can account for the
energy of the complex but do not indicate the shape of the
potential energy surface (PES), which describes how rigid the
complex is. When two molecular species come into proximity,
the potential energy surface can involve a narrow minimum or
a wide one (Fig. 1A). A narrow minimum corresponds to
a rigid complex and a greater entropy penalty than a wider
minimum. Diﬀerent interaction types make diﬀerent contri-
butions to the shape of the PES. Density functional theory
calculations were used to investigate how the energy of the
system changes as several functional groups approach one
another. The full set of calculations is described in the ESI
(section S1†) but the key results can be summarized by
considering water and methane as examples of polar and non-
polar functional groups, respectively (Fig. 1B). Only when two
polar groups (appropriately oriented) or charged groups of
opposite sign approach one another is there a well-dened
energy minimum; only polar–polar interactions tend to
increase complex rigidity. It is of course the case that even
many polar groups will have a repulsive interaction when the
polarities are mismatched and that two non-polar groups that
are aromatic rings can give a shallow energy minimum.44 To
understand the thermodynamics of a gas phase binding event
(DHcorr(gas)  TDS(gas)), it is important to consider the rela-
tive contribution of polar and non-polar groups. Furthermore,
the solvation free energy of the ligand and of the complex in
water will be enhanced by the presence of polar groups on the
ligand and diminished by non-polar regions. The solvation
free energy of the protein is a constant and so accounting for
whether the groups involved in binding are polar or non-polar
oﬀers a simple way to account for the change in solvation free
energy (DDGsolv).
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 2218–2227 | 2219
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Medicinal chemists have been concerned about the inu-
ence of non-polar groups upon binding aﬃnity for some time
and log P has been used to diﬀerentiate ligands that rely
primarily upon polar interactions from those that are hydro-
phobic.45–47 The partition coeﬃcient, P, and its logarithm are
convenient parameters because they are easily measured and
can be accurately predicted.45 It is our hypothesis that a ligand's
log P can serve as a surrogate for the three terms on the right of
eqn (1) when computing its binding free energy.48 This leads us
to propose that for a given system, binding aﬃnity can be
described by eqn (3).
Affinity ¼ aDE + b log P + g (3)
where a, b and g are constants for that system. We propose
obtaining values for these empirically and DE is dened by eqn
(2), where E indicates a quantum mechanical energy that is
obtained with no vibrational corrections included. The energy
of the receptor (Ereceptor) in this equation is arbitrary because it
is constant for all ligands but it will inuence the resulting value
of both a and g. A range of aﬃnity assessment types (IC50, Ki, Kd,
etc.) can be used but should all be transformed such that they
will have a linear relationship with energy. We do this by
transformation to pIC50, pKi, pKd such that improved aﬃnity
corresponds to increasing values of each of these properties;
a should therefore be negative and b positive if more negative
values of DE and increased lipophilicity correspond to tighter
binding. In order to obtain values for the three constants, at
least three compounds of known aﬃnity are required and thus,
like the linear interaction energy approach, only relative aﬃnity
can be computed.49 DE would usually be computed using the
lowest energy protein–ligand complex and lowest energy
conformation of the free ligand and therefore, be relevant to
cases where the bound state is dominated by one geometry.16
However, the approach can be simply adapted to include
multiple low energy conformations (of bound or free states)
using a Boltzmann weighting scheme. The exible form of eqn
(3) naturally ameliorates other deciencies of the calculations
including the exclusion of longer range interactions (primarily
electrostatic) with the regions of the protein that are not
included in the theoceptor and deciencies in the continuum
part of any solvation models that are used (such as inappro-
priate values of the dielectric of the medium). It is challenging
to predict the dielectric that the protein environment provides
and so we take advantage of this approach by treating the
protein using gas phase calculations with no continuum
solvation.
The eﬀect of eqn (3) is that for a polar ligand that makes
a full set of polar interactions with the receptor, DE will be large
and negative and this will oﬀset the low log P term. A polar
ligand that does not make a satisfactory set of polar interactions
will have a less benecial DE term that will not be suﬃcient to
counteract the small log P contribution. A largely hydrophobic
ligand will also have a smaller contribution to binding aﬃnity
from DE but this might be oﬀset by the hydrophobicity term.
There have been a number of reports in which quantum
mechanical calculations have been used to compute binding
energies for protein–ligand and other host–guest interactions.
Energy diﬀerences are computed with no vibrational correc-
tions and provide data with which this concept can be tested (in
certain cases, the log P values have been computed by
ourselves). The examples (Table 1) include: (A) Roos et al. who
looked at the relative binding aﬃnities of a matched series of
mineralocorticoid receptor (MR) agonists, using a range of DFT
methods, withM062X performing the best.50 (B) Investigation of
inhibitors of the dimerisation of inducible NO-synthase by
Leach et al.51 This system includes backbone atoms of six resi-
dues forming the binding site, an iron porphyrin and its
attached cysteine thiol. Among the QM methods tried, M06HF
performed the best. (C) Roos et al. who used DFT to explore the
relationship between the measured and predicted aﬃnities for
a set of positively charged amidine and guanidine cores binding
to the b-site of APP cleaving enzyme (BACE-1).52 (D) Hylsova´ and
co-workers, who have studied a series of pyrazolopyrimidine
inhibitors of the kinase CDK2.53
As shown in Fig. 1C and section S2,† in each of these
examples, incorporating log P improved the description of
measured binding aﬃnity by the QM energies. To make the
Fig. 1 (A) The diﬀerence between a rigid and a loose complex illustrated by the change in energy as ligand and receptor approach one another.
(B) Variation in electronic energy (M06/6-31+G**) as non-polar groups and/or polar groups approach one another. (C) Example protein–ligand
and host–guest systems studied with QM calculations. Top: experimental aﬃnity is plotted against computed energies, DE; bottom: log P term is
added.
2220 | Chem. Sci., 2019, 10, 2218–2227 This journal is © The Royal Society of Chemistry 2019
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comparison in the most straightforward way, two-parameter
linear regression has been performed using rstly DE and
calculated log P as independent variables and secondly DE and
a random value that spans the same range as the log P values.
The statistics for the second cannot be worse than those for the
single parameter model using only DE. The resulting R2 and
RMSE values are shown in Table 1. In all cases, the addition of
log P improved the correlation. For system A, Roos et al. also
performed FEP calculations and achieved a correlation with R2
of 0.60 and RMSE of 0.73 (worse correlation is found when
correlating with pKi–log D instead of just pKi).
52
The values obtained for the coeﬃcients in eqn (3) are
shown in Table 1, along with the standard deviation obtained
from systematic leave-one-out analysis. It is likely not a coin-
cidence that the BACE inhibitors (b ¼ 0.24) are binding to
a highly polarized dianionic binding site while the iNOS
inhibitors (b ¼ 1.22) bind to a site dominated by the hydro-
phobic porphyrin of heme and MR agonists (b ¼ 1.58) are
binding to sites which lack substantial polarity (a lone threo-
nine provides a point of polar interaction). The CDK2 binding
site (b¼ 0.88) includes hydrophobic residues and several polar
interactions. The more hydrophobic the binding site, the
higher the value of b.48 The same approach is also applicable
to organic host–guest systems in water. For instance: (E) in
their computational studies of a set of carboxylic acids
binding to an octa-acid cavitand, Mikulskis et al.54 compute
binding energies using several DFT methods and achieve their
best results (before the addition of vibrational corrections)
with BP86/TZVP when Cosmo solvation is included in their
calculations. (F) Kimura, Yukiyama and Fujisawa studied the
complexation of a series of nitriles by an a-cyclodextrin host in
water and performed calculations at the B3LYP/6-31++G**
level to rationalize their observations. In both cases, the
agreement between computation and experiment is enhanced
when eqn (3) is applied. In the case of these two organic hosts,
the values of b are higher than for the protein–ligand systems.
This likely reects the absence of polar groups inside the
cavities (unlike proteins which must contain amide groups).
The sets of compounds studied in host–guest interactions are
smaller than for the protein–ligand binding examples and this
likely explains the larger standard deviations observed for the
values of the coeﬃcients in Table 1. Naturally, the organic
hosts are more challenging to study with force eld-based
approaches because they would require parameters to be
developed for both the host and guest.
To investigate the utility of the theoceptor approach, it has
been applied to a system of therapeutic interest: Lactate Dehy-
drogenase A (LDHA). LDHA catalyses the reversible conversion
of pyruvate to lactate, with the concomitant conversion of
NADH to NAD+. Several classes of cancers are characterised by
elevated levels of lactate, and LDHA is overexpressed in human
tumors.56–61 As such, inhibitors of this enzyme have been sought
as potential therapeutics. Several classes of inhibitors of LDHA
have been described and a wealth of structural information and
binding aﬃnity data are available.62–77 The set of compounds (1–
11) studied include seven from high-throughput screening
(HTS) of the Genentech/Roche corporate compound collec-
tion;66,68,69,71,72,78 two small, negatively charged compounds;73
and three compounds sharing malonate as a common
substructure originating from AstraZeneca's fragment
screening approach (Table 2, Fig. 2).74 The selective and potent
LDHA inhibitors discovered so far exhibit a common structural
feature: a carboxylic acid moiety (or other acidic functional
group) that is ionized at physiological pH. Structural studies
reveal that in the binding site, this is placed in close proximity
to where the acid in the substrates and products binds. All
interact with the basic side-chain of Arg168.
Structures of 1–7 are all available in complex with human
LDHA.66,68–70,72 Crystal structures of 8 and 10 are available in
complex with rat LDHA (PDB codes 4AJE and 4AJI),79 and the
structure of 11 is available in complex with rabbit LDHA (PDB
code 4I8X).80 It should be recalled that these structures are
proposed interpretations of the observed electron density and
alternative interpretations may also be reasonable. While global
metrics such as resolution have their place for assessing the
structures, more localised values prove instructive when
focusing on the ligands. One of the most common metrics for
assessing the t of a proposed structure to the local electron
density is the real space-correlation coeﬃcient (RSCC). It ranges
from 0 (‘bad’, electron density is eﬀectively missing) to 1 (‘good’,
model ts the density perfectly).81–83 RSCC values for the
selected ligands are given in Table 2. Density maps contoured at
1s of the ligands with lower RSCC values (ligands 1, 2, 6 and 7)
are shown in section S5.†
Residues directly involved in ligand binding were selected as
a part of the theoceptor: Arg168, His192, Val234, Asp165,
Table 1 Protein–ligand and host–guest systems (see text) studied by QM and reevaluated by ourselves. Pearson's correlation coeﬃcients (R2)
and root-mean-squared errors (RMSE) describe the link between aﬃnity and DE when combined with log P or a random number. The coef-
ﬁcients for eqn (3) are also provided
System
DE + random DE + log P
a b gR2 RMSE R2 RMSE
A 0.51 0.85 0.83 0.51 0.35  0.01 1.58  0.10 4.71  0.17
B 0.67 1.00 0.93 0.46 0.28  0.01 1.22  0.04 6.68  0.23
C 0.67 0.52 0.71 0.48 0.32  0.01 0.24  0.01 0.13  0.01
D 0.61 0.65 0.82 0.45 0.10  0.00 0.88  0.04 9.50  0.28
E 0.55 3.11 0.73 2.41 0.08  0.02 5.10  0.78 3.02  1.84
F 0.33 2.37 0.75 1.45 0.50  0.16 3.39  0.58 10.26  1.35
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 2218–2227 | 2221
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Asp194, Tyr238, and Asn137 (Fig. 3). These were extracted
from the structure deposited in the PDB with the code 4QO7
(theoceptors derived from other protein structures performed
equivalently). Protonation states were assigned such that
Arg168 is protonated, Asp165 and Asp194 are both deproto-
nated and His192 is protonated in order to form a stabilizing
interaction with Asp165 and the net charge of the residues was
0. There are two noteworthy changes in the sidechain
conformations amongst the deposited structures but one
arrangement is clearly most relevant to the bound state in
humans: Arg105 protrudes into the binding site in rat and
rabbit structures as well as in the apo form of human LDHA
but in the holo forms of the human protein, it interacts with
Glu191 instead (and so it is excluded from the theoceptor)
while Tyr238 moves out of the binding site only in the apo
form (and hence is included). Asp165 forms a hydrogen bond
with His192 and is stabilised by an additional hydrogen bond
with one water molecule. Preliminary studies showed that the
water molecule maintains the sidechain in an optimal posi-
tion to interact with the His192 sidechain and so is considered
structural and was kept in the theoceptor (Fig. 3, insert). All
interactions with the ligand are through protein sidechains so
backbone, cofactor and the remainder of the protein were
deleted. To account for the scaﬀolding eﬀect of the rest of the
protein, Ca, Cb and water oxygen atoms were xed in space
using the xed Cartesian redundant coordinate feature in
Gaussian 09,84 as shown in Fig. 3. The geometries were opti-
mized in vacuo at the M06 level of theory with the 6-31+G**
basis set because this level of theory should provide a well-
balanced treatment of diﬀerent interaction types.85,86 Free
ligand structures were optimized with solvation incorporated,
using the PCM water model, at the same level of theory. DE
values were dened as in eqn (3) with Ereceptor being obtained
from a theoceptor calculation in which the ligand had been
deleted. The values of the coeﬃcients were a ¼ 0.080, b ¼
0.892 and g¼ 0.419 and yield the relationship shown in Fig. 3.
The value of b, when compared to those in Table 1, is
consistent with a binding site that is hydrophobic in parts
with a polar section, as included in the theoceptor. Protein–
ligand crystal structures are interpretations that are several
steps removed from the experimental measurements, and so
include uncertainties, many of which depend on the force
eld used during renement.12 QM calculations can help
discriminate amongst plausible interpretations of the
observed electron density. The chemical rigour demanded by
theoceptor calculations can improve: ligand conformations,
interpretations of the positioning of heteroatoms, stereo-
selectivity, positioning of ligands where electron density is
missing, assignment of tautomeric and ionisation states.87
Further, by studying a set of conformations (and tautomers
when relevant) of the free and bound ligand, diﬀerences
between the low energy conformations and the bioactive
conformation are identied and the conformer-focusing
problem can be addressed.88 Compounds where one or other
of these eﬀects were relevant are described.
2.1 Compound 1
The tetrahydropyran ring of ligand 1 is crystallographically
modeled in a boat conformation that yields a predicted aﬃnity
far from experiment. This is corrected when modeled as a chair;
the free conformation is 9 kcal mol1 lower than the boat and
the theoceptor with 1 in a chair conformation is 10 kcal mol1
lower in energy than with a boat conformation (Fig. 4). The
RSCC of the ligand was 0.94, which implies that the ligand ts
Table 2 Compounds selected for computational studies with experimental values of pIC50 and pKd, PDB identiﬁer and the chain label used to
compute the RSCC value for each ligand. The clog P was calculated using the ChemAxon55 log P predictor and DE was calculated with the
theoceptor method
Compound pIC50 pKd PDB code (chain) RSCC clog P DE (kcal mol
1)
1 7.22 NC 4R69 (D) 0.943 5.58 17.7
2 6.44 NC 4RLS (D) 0.883 4.97 13.8
3 5.76 5.46a 4QO7 (A) 0.958 2.86 23.2
4 8.22 NC 4R68 (B) 0.979 8.07 15.0
5 6.06 5.74a 4QO8 (A) 0.921 6.15 13.6
6 5.3 5.3a 4M49 (A) 0.816 3.81 10.3
7 6.12 5.29a 4JNK (D) 0.911 2.96 24.9
8 <3.3 3.67a, 3.33b 4AJE (B) 0.988 2.06 15.6
9 <3.3 2.96a, 3.63b 1.63 18.9
10 <3.3 3.55a, 3b 4AJI (B) 0.963 1.47 19.7
11 <2.7 2.63a 4I8X (B) 0.913 2.45 10.4
a Obtained by SPR. b Obtained by NMR
Fig. 2 Structures described in the text.
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the density well. However, the density contoured at 1s reveals
that both chair and boat would t equally well; the diﬀerenti-
ating part of the density is absent.
In order to investigate this further, the deposited structure
was re-rened (using the PHENIX suite of soware)41,88 using
two alternative sets of restraints on the conformation of the
Fig. 3 Theoceptor for the LDHA nicotinamide site taken from the complex with 3 (shown in grey). Ca, Cb (spheres) and water oxygen (red sphere)
were ﬁxed during the QM optimization. The insert shows the hydrogen bonding network involving a water molecule, Asp165 and His192.
Measured aﬃnity is plotted against computed aﬃnity for compounds 1–11, oxamate and malonate. R2 ¼ 0.85 and RMSE ¼ 0.76.
Fig. 4 Theoceptor optimized structures described in the text.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 2218–2227 | 2223
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tetrahydropyran ring: one in which the ring is kept as a chair
and one as a boat. In this structure, the ligand is present in all
four protein molecules in the asymmetric unit. Subsequent to
the single round of renement, omit maps were generated in
which the remainder of the structure is used to compute the
phasing and the density in the omitted region (the ligand).
These maps are shown for the four ligands present in the
asymmetric unit in Fig. 5 and conrm that the available density
cannot provide a denitive conformation for this ring. Better
statistics were obtained for the boat conformation (the all boat
structure achieved Rwork of 0.1553 and Rfree of 0.2568 while the
all chair structure achieved Rwork of 0.1575 and Rfree of 0.2574).
Inappropriate restraints and the statistics used to analyze the
outcome misled the original renement resulting in the wrong
ligand conformation. Occasionally (see below) the correct
conformation of a ring will not be so trivial and in these
circumstances a quantum mechanical binding energy that
accounts for the conformational preference of the ligand in the
eld of the protein can provide a very useful companion to
a structural renement.
2.2 Compound 2
The RSCC for ligand 2 of 0.83 suggests that it does not t the
density map accurately and inspection reveals that the density
around the indane moiety is missing. The rst step to model this
compound was to determine the preferred position of the oxygen
atom in the dihydropyrone ring, because this can easily be mis-
placed when interpreting electron density maps.12 Changing the
position of the oxygen atom inverts the conguration of the ster-
eocentre. This compound was obtained as a single, unknown
enantiomer and its absolute stereochemistry was assigned as R by
Fauber et al. on the basis of the protein–ligand crystal structure.68
The energy diﬀerence between the theoceptor optimized with the
oxygen in each of the two possible positions was less than
0.2 kcal mol1, indicating that the ring oxygen is not interacting
with the theoceptor and the proposed positioning is reasonable.71
The missing electron density around the indane moiety would be
consistent with the phenyl substituent adopting pseudo-axial or
pseudo-equatorial orientations, relative to the dihydropyrone ring.
In the free ligand, the diﬀerence between these two conformations
is less than 0.1 kcal mol1 but in the complex with LDHA, the
conformation with the phenyl in the pseudo-axial conformation is
8 kcal mol1 lower in energy than in the pseudo-equatorial
conformation (Fig. 4). This energy change originates from addi-
tional edge to face stacking between the ligand in its pseudo-axial
conformation and tyrosine (Fig. 4, with the R stereochemistry
retained for ease of comparison). We therefore propose a bound
structure in which the position of the ring oxygen is maintained
but the phenyl group is in the pseudo-axial position. This provides
a better interpretation of the experimental data and suggests that
the absolute stereochemistry is likely to have been misassigned
based on the deposited crystal structure and is actually S.
To investigate this possibility, the deposited structure was re-
rened. In this case, the ligand is only present in one of the
proteins in the asymmetric unit and geometries of the two
stereoisomers and two conformations were created in GaussView
and were overlaid onto the ligand in the deposited structure
using the pair_t command in pymol.89,90 These initial positions
were used to initiate a rst round of renement in PHENIX. The
resulting ligand geometries were extracted and used to create
a set of restraints in the eLBOW tool.91 These were then used
during a second round of renement in PHENIX that was
analyzed with omit maps. The values of Rwork and Rfree obtained
during this phase are provided in Fig. 5. The renement statistics
for the axial conformations are inferior to those for the equato-
rial. However, the maps in Fig. 5 reveal that the aromatic ring is
not strongly supported in either position by the available exper-
imental evidence. In this case, even though the structure has
a reasonable overall resolution of 1.91 A˚, expanding the evidence
base for the structure to include theoceptor energies would
permit a better-informed determination of the conformation and
therefore the identication of the stereochemistry would be
placed on a stronger footing. Ensuring that chemical insight
(using knowledge or quantum mechanically derived energies) is
involved in dening the conformational preferences of ligands
when in protein binding sites should ensure that correct deduc-
tions are more likely to be made from these structures.
2.3 Compound 11
As with the oxygen atom in 2, the pyridine nitrogen in 11 is
impossible to place with certainty at 2.2 A˚ resolution.12 In this
case, the theoceptor nds an energy diﬀerence of 4 kcal mol1
favouring the ligand with nitrogen oriented as in the deposited
structure. This preference is due to an interaction of the pyri-
dine nitrogen with a positively charged environment formed by
the sidechains of His192 and Asn137. The theoceptor provides
extra support for the deposited structure.
2.4 Compound 3
The phenyl substituent in ligand 3 is in an axial position relative
to the 3-hydroxycyclohexenone ring in the deposited structure.
Somewhat surprisingly, axial and equatorial ligand conforma-
tions were computed to be energetically indistinguishable inFig. 5 Re-reﬁned structures and omit maps (see text).
2224 | Chem. Sci., 2019, 10, 2218–2227 This journal is © The Royal Society of Chemistry 2019
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the unbound state (energy diﬀerence ¼ 0.6 kcal mol1). In 3
there are no axial hydrogens located on the same face of the ring
as the phenyl group and consequently, no clashes. However,
there is a clear preference in the bound state: the theoceptor
with the ligand in an equatorial conformation is 4 kcal mol1
higher in energy. This diﬀerence originates from protein–ligand
edge to face stacking present when the ligand is in an axial
conformation (Fig. 5). In this case the theoceptor conrms the
surprising conformation that had been proposed for 3.
2.5 Compounds 8–10
Initial positioning of the malonate derivatives was carried out
by superimposing the malonate moiety on the 3-hydroxy
cyclohexenone ring of ligand 3, to place it in close proximity to
the basic side chain of Arg168. The malonate moiety of
compound 9 was rst modeled in its dianionic form; the
resulting complexation energy (DE) of +44 kcal mol1 is not in
the range found for other ligands described here. This arises
due to the loss of solvation energy that is not compensated by
suﬃcient interactions in the receptor. These ndings suggest
that the malonate moiety may bind in a mono-deprotonated
form. Three diﬀerent malonate positions were investigated for
monoanionic 9 in the theoceptor. The lowest energy theoceptor
was the one where the malonate moiety made four hydrogen
bonds with the nearby sidechains (18.9 kcal mol1). The
energy diﬀerence of 15 kcal mol1 between the highest and
lowest energy theoceptor emphasizes the eﬀect subtle confor-
mational changes of the interacting groups can have on the
overall binding energy, particularly when strongly interacting
groups such as anions are involved.
2.6 Malonate and oxamate
When considering the binding of malonate itself, a total of 8
diﬀerent malonate tautomeric monoanions were optimized in
solution and all were found to be energetically indistinguish-
able (within a range spanning 0.5 kcal mol1). The correct
orientation of malonate in the binding cavity could also not be
condently determined: optimization of 8 diﬀerent theo-
ceptors, each with a diﬀerent malonate starting position
resulted in complexes with DE values ranging from 8 to
+16 kcal mol1. These ndings, in conjunction with experi-
mental ambiguity concerning the state of the protein during the
experimental measurements, suggested that malonate may
bind in the presence of and proximal to cofactor NAD+/NADH.74
Calculations employed the oxidized and reduced form of nico-
tinamide with the ribose present but with the phosphate moiety
truncated to a methyl group.92 The DE with co-factor in its
reduced form was 5.4 kcal mol1 and in its oxidized form
almost 40 kcal mol1, which is consistent with the experi-
mental aﬃnities. Finally, the binding of oxamate was investi-
gated. Again, binding is facilitated by the co-factor: the energy
diﬀerence between the theoceptor with and without co-factor
bound was more than 50 kcal mol1 (Fig. 4). These ndings
are very interesting from the drug designer's point of view: small
negatively charged molecules that mimic substrate and bind in
the presence of co-factor (rather than competing with it) have
the tendency to be more eﬃcient binders. As these studies were
underway, a publication disclosed a new inhibitor, 12, in which
a nitrogen has been introduced into the central ring of
compounds like 1, 3, 4 and 5.64 This provided an opportunity to
test the predictive capability of the theoceptor. The calculations
for compound 12 yielded a DE of 19.5 kcal mol1 and log P of
3.84. These gave a predicted pIC50 of 5.41. The experimental
work had measured the pIC50 to be 5.40, which is in excellent
agreement with the prediction. Furthermore, the calculations
reveal that when the ligand is outside the protein, the pseudo-
axial and pseudo-equatorial conformations are within
0.4 kcal mol1 but in the binding site, the axial is preferred by
5 kcal mol1. As with compounds 2 and 3, this is due to edge to
face interactions with tyrosine (Fig. 4). The favored structure
sees the introduced NH group on the opposite side of the ligand
to the NH in the sidechain of Asn137; the alternative position is
computed to be 1 kcal mol1 higher in energy. The preferred
stereoisomer is therefore S-12 (the original publication does not
explore the stereochemical preference for this molecule).
3 Conclusions
The combination of computed quantum mechanical binding
energies with measured or predicted ligand log P values can
provide usefully accurate predictions of host–guest and protein–
ligand binding energies. By assigning relative energies to protein–
ligand structures in which diﬀerent conformations, tautomers,
protonation states and stereoisomers are sampled, useful insights
about the interactions between the protein and ligand are gener-
ated. This can include regions that are not observed in the
experimental electronic density. Computed structures reveal the
limitations of the statistics currently used during the renement of
X-ray crystal structures. Our approach is suﬃciently accurate to
make useful predictions about the aﬃnity for new compounds.
Chemists must become proactive creators of protein–ligand
crystal structures rather than passive consumers; quantum
mechanics provides a useful tool to do this in an objective fashion.
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